Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoantigen DNA Vaccine in Pancreatic Cancer
NCT03122106Phase 1Terminated
- Sponsor
- Washington University School of Medicine
- Start
- Jan 2018
- Primary completion
- Sep 2021
- Modality
- Prophylactic Vaccines, DNA Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of polyepitope neoantigen dna vaccine in pancreatic adenocarcinoma (PDAC), sponsored by Washington University School of Medicine. Primary endpoint: Safety of Neoantigen DNA Vaccine as Measured by the Number of Subjects Experiencing Each Type of Treatment-related Adverse Event. Started Jan 2018; status: terminated.
02
Drugs
polyepitope neoantigen dna vaccine
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT03122106.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03122106.